No Single Blood Test Detects All Cancers
Currently, there is no blood test that can detect all types of cancer, but emerging multi-cancer early detection (MCED) tests can screen for multiple cancers simultaneously—though with important limitations you need to understand.
What MCED Tests Actually Do
MCED tests analyze cell-free DNA methylation patterns or other biomarkers in blood to detect cancer signals from multiple cancer types at once. The most studied tests include:
- Galleri®: Detects signals from over 50 cancer types with sensitivity of 20.8-66.3% and specificity of 98.4-99.5% 1
- CancerSEEK: Screens for 8 cancer types with sensitivity of 27.1-62.3% and specificity of 98.9-99.1% 1
- Other tests (SPOT-MAS, Trucheck, etc.) show variable performance 1
Real-world data from over 111,000 individuals showed a cancer signal detection rate of only 0.91%, with 258 confirmed invasive cancers spanning 32 cancer types 2. The test correctly predicted the cancer location in 87% of cases 2.
Critical Limitations You Must Know
Sensitivity Problems
- Early-stage detection is poor: Sensitivity is significantly lower for stage I-II cancers compared to stage III-IV disease 1
- Many cancers are missed: Even the best tests miss 30-80% of cancers depending on type and stage 1
- Not all cancer types covered: No test truly detects "all" cancers
Current Clinical Status
No MCED test is FDA-approved or endorsed by any clinical practice guideline 3. Most insurance does not cover these tests 3. The evidence base consists of no completed randomized controlled trials demonstrating mortality benefit 1.
What This Means for Your Practice
If a Patient Asks About MCED Testing
Do not feel obligated to initiate discussions about MCED testing, but engage patients who inquire through shared decision-making 3. Key discussion points:
- These tests are investigational and not replacements for standard screening
- High false-positive rates (1-2%) mean many healthy people will undergo unnecessary workups 1
- Negative results do not rule out cancer
- Most importantly: Complete all guideline-recommended cancer screenings regardless of MCED test results 3
If a Patient Has a Positive MCED Result
The cancer signal origin (CSO) prediction guides diagnostic workup, with median time to cancer diagnosis of 39.5 days from result receipt 2. However, diagnostic resolution pathways remain unstandardized 4.
Common pitfall: Assuming a negative MCED test means no cancer is present—sensitivity is too low to rule out disease.
The Bottom Line
While MCED technology shows promise for detecting cancers without standard screening modalities 5, these tests supplement but do not replace guideline-recommended cancer screening 3. In the DETECT-A trial, 50% of MCED-detected cancer patients were alive and cancer-free at 4.4 years, particularly those diagnosed at early stages 5. However, without randomized trial data on mortality reduction, these tests remain experimental tools that require careful patient counseling about benefits, harms, and uncertainties 3, 1.